深部热疗联合替雷利珠单抗和化疗治疗晚期肺鳞癌的临床疗效和安全性OA

Objective To analyze the clinical effect of deep hyperthermia combined with tislelizumab and chemotherapy in the first-line treatment of advanced lung squamous cell carcinoma.Methods Thirty-nine patients with advanced lung squamous cell carcinoma diagnosed by histopathology or cytology who received deep hyperthermia combined with tislelizumab(200 mg once every 3 weeks,applied on the first day of chemotherapy)and chemotherapy(injection of albumin-bound paclitaxel 260 mg/m2,d1,d8,combined with nedaplatin 80-100 mg/m2,d1-4,every 3 weeks)at the Third Hospital of Shijiazhuang from January 2021 to December 2023 were collected.The target area of deep hyperthermia was the projection site of primary lung lesions and mediastinal lymph node metastases.The duration of each deep hyperthermia session was 40 min.The tumor remission,adverse reactions and survival of the patients were analyzed.Results The median follow-up time was 23 months.After the treatment,22 cases(56.4%)achieved partial response,and the disease control rate was 84.6%(33/39).The most common adverse reactions were leukopenia,anemia,thrombocytopenia,nausea and vomiting,which were mainly grade 1-2.The incidence of immune-related adverse events was 17.9%(7/39),all of which were grade 1-2.The 2-year overall survival rate was 52.2%,and the 2-year progression free survival rate was 37.4%.Conclusions Deep hyperthermia combined with tislelizumab and chemotherapy can improve the short-term efficacy of patients with advanced lung squamous cell carcinoma,and the adverse reactions are manageable.